A lower number of viable pre-leukemic cells carrying the Sfpi1 deletion translates to a lower probability of malignant cell formation and rAML onset during a mouse’s lifespan, hence explaining the difference in rAML incidence depending on the HRS status. The gene discussed is SPI1; the disease is kidney angiomyolipoma.